Stockscreener 앱 받기
0.95
1.55%
-0.015
시간 외 거래:
1.00
0.05
+5.26%
전일 마감가:
$0.965
열려 있는:
$0.96
하루 거래량:
91,725
Relative Volume:
0.44
시가총액:
$15.84M
수익:
$486.00K
순이익/손실:
$-28.43M
주가수익비율:
-0.337
EPS:
-2.8189
순현금흐름:
$-26.75M
1주 성능:
-8.65%
1개월 성능:
-32.62%
6개월 성능:
-67.91%
1년 성능:
-62.75%
1일 변동 폭
$0.95
$0.9903
1주일 범위
$0.95
$1.0899
52주 변동 폭
$0.95
$4.30
Vyne Therapeutics Inc Stock (VYNE) Company Profile
명칭
Vyne Therapeutics Inc
전화
800-775-7936
주소
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
VYNE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.95 | 17.33M | 486.00K | -28.43M | -26.75M | -2.8189 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 개시 | BTIG Research | Buy |
| 2021-12-06 | 재개 | H.C. Wainwright | Buy |
Vyne Therapeutics Inc 주식(VYNE)의 최신 뉴스
VYNE Therapeutics (NASDAQ:VYNE) Upgraded at Wall Street Zen - Defense World
VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges - Investing.com India
VYNE Therapeutics (NASDAQ:VYNE) Cut to Sell at Wall Street Zen - Defense World
VYNE Stock Touches 52-Week Low at $1.17 Amid Market Challenges - Investing.com
VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail
VYNE Therapeutics Reports Q1 2025 Financial Results - TipRanks
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating - TipRanks
Vyne Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
VYNE Therapeutics Inc Q1 2025 Earnings: EPS of -$0.20 Beats Estimate, Revenue of $0.2 Million Exceeds Forecast - GuruFocus
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - The Manila Times
Renaissance Technologies LLC Decreases Stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) - Defense World
VYNE Therapeutics Inc (VYNE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Closing Strong: VYNE Therapeutics Inc (VYNE) Ends at 1.43, Down -23.94 from Last Close - DWinneX
Market Watch: Renovaro Inc (RENB)’s Noteworthy Gain, Closing at 0.37 - DWinneX
The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com
HC Wainwright Cuts VYNE Therapeutics (NASDAQ:VYNE) Price Target to $4.50 - Defense World
FDA places clinical hold on VYNE’s psoriasis drug study - Investing.com
VYNE stock touches 52-week low at $1.38 amid market challenges - Investing.com
After A -27.64% Drop In Share Price, Is VYNE Therapeutics Inc (NASDAQ:VYNE) A Better Trade Than Others? - Marketing Sentinel
FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - AOL.com
VYNE Therapeutics Inc (VYNE) Stock: A Year of Highs and Lows in the Market - investchronicle.com
VYNE stock touches 52-week low at $1.38 amid market challenges By Investing.com - Investing.com South Africa
FDA places clinical hold on VYNE’s psoriasis drug study By Investing.com - Investing.com South Africa
VYNE Therapeutics Provides Update on VYN202 Program | VYNE Stock News - GuruFocus
VYNE’s earnings forecast for the current quarter - uspostnews.com
VYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down. - Nasdaq
FDA Places Clinical Hold on VYNE’s VYN202 Phase 1b Trial for Plaque Psoriasis - Dermatology Times
VYNE Therapeutics (VYNE) Target Price Cut Following FDA Clinical - GuruFocus
VYNE Therapeutics (VYNE) Faces FDA Clinical Hold on Psoriasis Dr - GuruFocus
With 36.89% Distance From Low, Could Vs Media Holdings Ltd (NASDAQ:VSME) Post Further Gains? - Marketing Sentinel
Pre-market Movers: OMEX, SES, VYNE, OLB, LEXX… - RTTNews
VYNE Says FDA Halted Psoriasis Drug Trial After Signs of Toxicity Found; Shares Down Pre-Bell - marketscreener.com
VYNE Therapeutics Provides Update on VYN202 Program - The Manila Times
VYNE Therapeutics Psoriasis Drug Trial Suspended: FDA Flags Critical Safety Issues in Animal Studies - Stock Titan
VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 1.1% – Here’s What Happened - Defense World
Is VYNE Therapeutics Inc (NASDAQ: VYNE) A Suitable Stock For New Investors Today? - Stocksregister
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - Yahoo Finance
Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Update - Defense World
Vyne therapeutics director Patrick Lepore buys $43,800 in stock - MSN
Invesco Canada announces cash distributions for its ETFs - The Globe and Mail
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times
VYNE Therapeutics Showcases Breakthrough Autoimmune Disease Treatments at Major Conference - StockTitan
Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga
VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright - Defense World
VYNE Therapeutics Reports Progress in Clinical Trials - TipRanks
VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
VYNE Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Est - GuruFocus.com
Vyne Therapeutics Inc (VYNE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):